181 related articles for article (PubMed ID: 11205628)
1. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s.
Maschmeyer G; Braveny I
Eur J Clin Microbiol Infect Dis; 2000 Dec; 19(12):915-25. PubMed ID: 11205628
[TBL] [Abstract][Full Text] [Related]
2. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.
Todeschini G; Franchini M; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Murari C; Ricetti MM; Perona G
Int J Infect Dis; 1998-1999 Winter; 3(2):99-104. PubMed ID: 10225988
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor.
Joo EJ; Kang CI; Ha YE; Kim J; Kang SJ; Park SY; Lee NY; Wi YM; Chung DR; Peck KR; Song JH
J Infect; 2011 Sep; 63(3):207-14. PubMed ID: 21777616
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa infection in cancer patients.
Rolston KV; Bodey GP
Cancer Invest; 1992; 10(1):43-59. PubMed ID: 1735012
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
Yan LZ; Herrington JD
J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
9. P. aeruginosa bloodstream infections among hematological patients: an old or new question?
Cattaneo C; Antoniazzi F; Casari S; Ravizzola G; Gelmi M; Pagani C; D'Adda M; Morello E; Re A; Borlenghi E; Manca N; Rossi G
Ann Hematol; 2012 Aug; 91(8):1299-304. PubMed ID: 22349723
[TBL] [Abstract][Full Text] [Related]
10. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.
Chatzinikolaou I; Abi-Said D; Bodey GP; Rolston KV; Tarrand JJ; Samonis G
Arch Intern Med; 2000 Feb; 160(4):501-9. PubMed ID: 10695690
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1.
Vidal F; Mensa J; Martínez JA; Almela M; Marco F; Gatell JM; Richart C; Soriano E; Jiménez de Anta MT
Eur J Clin Microbiol Infect Dis; 1999 Jul; 18(7):473-7. PubMed ID: 10482023
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.
Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT
Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology.
Tacconelli E; Tumbarello M; Bertagnolio S; Citton R; Spanu T; Fadda G; Cauda R
Emerg Infect Dis; 2002 Feb; 8(2):220-1. PubMed ID: 11897080
[No Abstract] [Full Text] [Related]
17. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
Lee CC; Lee CH; Hong MY
Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.
Grisaru-Soen G; Lerner-Geva L; Keller N; Berger H; Passwell JH; Barzilai A
Pediatr Infect Dis J; 2000 Oct; 19(10):959-63. PubMed ID: 11055596
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
